These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 2232500)

  • 1. Influence of converting enzyme inhibition on glomerular filtration rate and proteinuria.
    Rodicio JL; Alcazar JM; Ruilope LM
    Kidney Int; 1990 Oct; 38(4):590-4. PubMed ID: 2232500
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of angiotensin converting enzyme inhibitors on the progression of renal failure and proteinuria in humans.
    Rodicio JL; Praga M; Alcazar JM; Oliet A; Gutierrez-Millet V; Ruilope LM
    J Hypertens Suppl; 1989 Sep; 7(7):S43-7. PubMed ID: 2693657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Converting enzyme-inhibition in diabetic nephropathy.
    Mathiesen ER; Parving HH; Hommel E
    Contrib Nephrol; 1989; 73():160-1; discussion 161-2. PubMed ID: 2689092
    [No Abstract]   [Full Text] [Related]  

  • 4. The renal functional and structural consequences of corticosteroid and angiotensin-converting enzyme inhibitor therapy in chronic puromycin aminonucleoside nephropathy.
    Trachtman H; Del Pizzo R; Valderrama E; Gauthier B
    Pediatr Nephrol; 1990 Sep; 4(5):501-4. PubMed ID: 2242316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome.
    Van Dyck M; Proesmans W
    Pediatr Nephrol; 2004 Jun; 19(6):688-90. PubMed ID: 15064939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of angiotensin-converting enzyme inhibitor therapy on proteinuria in children with renal disease.
    Trachtman H; Gauthier B
    J Pediatr; 1988 Feb; 112(2):295-8. PubMed ID: 2828592
    [No Abstract]   [Full Text] [Related]  

  • 7. [Therapy with ACE inhibitors in chronic heart failure and limited kidney function].
    Osterziel KJ; Nagel F; Dietz R
    Z Kardiol; 1994; 83 Suppl 4():81-7. PubMed ID: 7856286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.
    Chiurchiu C; Remuzzi G; Ruggenenti P
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S58-63. PubMed ID: 15938036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Progression of renal dysfunction. Possibilities of nephroprotection with ACE inhibitors].
    Schollmeyer P; Lehnert T; Böhler J
    Internist (Berl); 1992 Aug; 33 Suppl 1():S46-52. PubMed ID: 1428698
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension.
    Zweifler AJ; Julius S; Nicholls MG
    Arch Intern Med; 1981 Jun; 141(7):907-10. PubMed ID: 6263204
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ACE inhibitors' effect on kidney function].
    Grönhagen-Riska C
    Nord Med; 1990; 105(8-9):219-22. PubMed ID: 2216687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
    Seeman T; Pohl M; Misselwitz J; John U
    Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases.
    Liou HH; Huang TP; Campese VM
    Nephron; 1995; 69(1):41-8. PubMed ID: 7891796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
    Lancet; 1997 Jun; 349(9069):1857-63. PubMed ID: 9217756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The comparative characteristics of the renal protective properties of angiotensin-converting enzyme inhibitors and calcium channel blockers].
    Kolesnyk MO; Lapchyns'ka II; Hromova AIe; Kassyr KhI
    Lik Sprava; 2000; (3-4):11-5. PubMed ID: 10921249
    [No Abstract]   [Full Text] [Related]  

  • 16. Conservative management of chronic kidney disease stage 5: role of angiotensin converting enzyme inhibitors.
    Dattolo PC; Gallo P; Michelassi S; Paudice N; Cannavò R; Romoli E; Fani F; Tsalouchos A; Mehmetaj A; Ferro G; Sisca S; Pizzarelli F
    J Nephrol; 2016 Dec; 29(6):809-815. PubMed ID: 27015900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of spironolactone in combination with angiotensin-converting enzyme inhibitors or Angiotensin receptor blockers in patients with proteinuria.
    Kim HY; Bae EH; Ma SK; Kim SW
    Kidney Blood Press Res; 2014; 39(6):573-80. PubMed ID: 25531940
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the angiotensin converting enzyme inhibitor, captopril, on proteinuria in chronic glomerular disease.
    Masunaga Y; Tabei K; Takeda S; Ando Y; Kusano E; Asano Y
    Nihon Jinzo Gakkai Shi; 1993 Aug; 35(8):961-6. PubMed ID: 8255007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S; Bigazzi R; Campese VM
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The use of angiotensin-converting enzyme inhibitors in patients with chronic glomerulonephritis].
    Dudar IO
    Lik Sprava; 1999; (7-8):55-9. PubMed ID: 10672690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.